For neuro-oncologists, much was accomplished in the last decade, including the establishment of the first standard of care (SOC) in this field of oncology. New treatment options boosted research in the whole field of neuro-oncology, as well clinical trials, translational and basic research. Accumulated data on molecular-genetic subgroups with distinct clinical outcomes in disease entities led to the establishment of new biomarkers and to the collaborative formulation of a new WHO classification of central nervous system tumors.
Keywords: Anaplastic glioma; CNS4+; Diffuse glioma; Glioblastoma multiforme; IDH1 mutation; Meningioma; Updated WHO classification of central nervous system tumors.